Derik De Bruin’s Buy rating for Quest Diagnostics is influenced by a variety of factors, including the company’s stable pricing outlook and robust M&A activity. The firm is entering 2024 with ...

Quest Diagnostics (DGX) appears an attractive ... only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the ...

Quest Diagnostics (DGX) appears an attractive ... only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the ...

In a report released on July 28, Ann Hynes from Mizuho Securities reiterated a Buy rating on Quest Diagnostics (DGX – Research Report), with a price target of $165.00. The company’s shares ...

Jefferies analyst Tycho Peterson assumed coverage of Quest Diagnostics (DGX) with a Buy rating and a price target of $185, up from $175. Larger full-service reference labs, such as Quest ...

Jefferies maintained their Buy rating and raised their price target to $190, signaling confidence in the company's stock performance going forward. In other recent news, Quest Diagnostics reported ...

Redburn-Atlantic sets Quest stock Buy rating, $195 target ...

Therefore, the Zacks rating upgrade for Quest Diagnostics basically reflects positivity ... and institutional investors typically buy or sell it. Their bulk investment action then leads to price ...

Jefferies lifts Quest Diagnostics stock target to $190, keeps Buy rating ...

Therefore, the Zacks rating upgrade for Quest Diagnostics basically reflects positivity ... and institutional investors typically buy or sell it. Their bulk investment action then leads to price ...

Quest Diagnostics (DGX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...